Randomized trial of cognitive speed of processing training in Parkinson disease
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To examine the efficacy of cognitive speed of processing training (SOPT) among individuals with Parkinson disease (PD). Moderators of SOPT were also examined.
Methods: Eighty-seven adults, 40 years of age or older, with a diagnosis of idiopathic PD in Hoehn & Yahr stages 1–3 and on a stable medication regimen were randomized to either 20 hours of self-administered SOPT (using InSight software) or a no-contact control condition. Participants were assessed at baseline and after 3 months of training (or an equivalent delay). The primary outcome measure was useful field of view test (UFOV) performance, and secondary outcomes included cognitive self-perceptions and depressive symptoms.
Results: Results indicated that participants randomized to SOPT experienced significantly greater improvements on UFOV performance relative to controls, Wilks λ = 0.938, F 1,72 = 4.79, p = 0.032, partial η2 = 0.062. Findings indicated no significant effect of training on secondary outcomes, Wilks λ = 0.987, F2,70 < 1, p = 0.637, partial η2 = 0.013.
Conclusions: Patients with mild to moderate stage PD can self-administer SOPT and improve their cognitive speed of processing, as indexed by UFOV (a robust predictor of driving performance in aging and PD). Further research should establish if persons with PD experience longitudinal benefits of such training and if improvements translate to benefits in functional activities such as driving.
Classification of evidence: This study provides Class III evidence that SOPT improves UFOV performance among persons in the mild to moderate stages of PD.
GLOSSARY
- CES-D=
- Center for Epidemiological Studies Depression Scale;
- MANOVA=
- multivariate analysis of variance;
- MMSE=
- Mini-Mental State Examination;
- MoCA=
- Montreal Cognitive Assessment;
- PD=
- Parkinson disease;
- RA=
- research assistant;
- SOPT=
- speed of processing training;
- UFOV=
- useful field of view;
- UPDRS=
- Unified Parkinson's Disease Rating Scale;
- USF=
- University of South Florida
Footnotes
The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the granting agencies.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Editorial, page 1278
- Received January 22, 2013.
- Accepted in final form May 31, 2013.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scoresMaureen Leehey, Sheng Luo, Saloni Sharma et al.Neurology, September 29, 2017 -
Articles
Visual dysfunction in Parkinson disease without dementiaE. Y. Uc, M. Rizzo, S. W. Anderson et al.Neurology, November 09, 2005 -
Articles
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson diseaseD. Weintraub, S. Mavandadi, E. Mamikonyan et al.Neurology, August 02, 2010 -
Article
CoQ10 in progressive supranuclear palsyA randomized, placebo-controlled, double-blind trialDiana Apetauerova, Stephanie A. Scala, Robert W. Hamill et al.Neurology: Neuroimmunology & Neuroinflammation, August 02, 2016